Focused On-demand Library for POC1 centriolar protein homolog A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8NBT0

UPID:

POC1A_HUMAN

Alternative names:

Pix2; Proteome of centriole protein 1A; WD repeat-containing protein 51A

Alternative UPACC:

Q8NBT0; A4FUW4; E9PFC6; Q0VDF8; Q2TAK6; Q96IK6; Q9UFJ8

Background:

POC1 centriolar protein homolog A (POC1A), also known as Pix2, Proteome of centriole protein 1A, and WD repeat-containing protein 51A, is pivotal in centriole assembly and stability, as well as ciliogenesis. It plays a crucial role in the early stages of centriole duplication and in the regulation of centriole length, working alongside POC1B to ensure centriole integrity and proper formation of the mitotic spindle.

Therapeutic significance:

The protein is linked to Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis, a syndrome marked by severe growth retardation and skeletal abnormalities. Understanding the role of POC1 centriolar protein homolog A could open doors to potential therapeutic strategies for this condition, by targeting the abnormal mitotic mechanics and impaired ciliogenesis observed in affected individuals.